Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 2/20 | 0.39 |
| ▸ | CCR3 | P51677 | 1/20 | 0.39 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12241769 | 0.89 | TP53 (0.45) | KLK7MEN1KMT2ATP53POLB | |
| SCHEMBL1594931 | 0.88 | P2RX7 (0.43) | KLK7HCRTR2HCRTR1 | |
| SCHEMBL1594928 | 0.88 | P2RX7 (0.43) | KLK7HCRTR2HCRTR1 | |
| SCHEMBL9929842 | 0.88 | FPR2 (0.39) | KLK7KMT2ATP53POLBKLK5 | |
| SCHEMBL9929841 | 0.88 | FPR2 (0.39) | KLK7KMT2ATP53POLBKLK5 | |
| SCHEMBL26439216 | 0.88 | VEGFA (0.41) | KLK7MEN1KMT2ATP53KLK5 | |
| SCHEMBL26707683 | 0.88 | VEGFA (0.41) | KLK7MEN1KMT2ATP53KLK5 | |
| SCHEMBL15383781 | 0.88 | KLK7 (0.51) | KLK7KLK5 | |
| SCHEMBL19419776 | 0.88 | KLK7 (0.51) | KLK7KLK5 | |
| SCHEMBL3728443 | 0.88 | KLK7 (0.51) | KLK7KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12144864-B2 | Tubulysins and protein-tubulysin conjugates | REGENERON PHARMACEUTICALS, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| CN-118027137-A | Tubulysin and protein-tubulysin conjugates | 里珍纳龙药品有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-113454097-A | Tubulysins and protein-tubulysin conjugates | 里珍纳龙药品有限公司 | 2021-09-28 | — | — | CN | disclosed |
| WO-2020132658-A2 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | REGENERON PHARMACEUTICALS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12144864-B2 | Tubulysins and protein-tubulysin conjugates | SDCBP, TEK, TEKT1 | KLK7 364/4885CCR3 1517/4885PLA2G7 2092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.